The Alpha Blend
Also known as: The Alpha Blend
A vendor-formulated multi-peptide research blend marketed around growth hormone secretagogue activity. It typically combines a GHRH analog with one or more ghrelin-receptor agonists for synergistic GH release.
Last updated
Mechanism of Action
The Alpha Blend is built around the established growth hormone secretagogue model in which a GHRH-receptor analog (such as CJC-1295 No DAC or a sermorelin-type peptide) amplifies pituitary GH pulse amplitude, while a selective ghrelin (GHS-R1a) receptor agonist such as Ipamorelin evokes an additional GH pulse. Because these components act on distinct receptor systems, their co-administration produces a synergistic, greater-than-additive release of pulsatile growth hormone and downstream IGF-1. The exact peptide ratios are proprietary to the vendor, but the pharmacology follows the standard dual-pathway GH secretagogue mechanism.
- Half-life
- Mixed and component-dependent: generally ~30 minutes to ~2 hours across the constituent secretagogues
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Studied for synergistic endogenous GH release
- Investigated for improved recovery and lean mass support
- Examined for enhanced sleep depth and quality
- Researched for IGF-1 elevation via natural pituitary pathways
- Studied for support of body composition and fat metabolism
Potential Side Effects
- Injection-site redness or transient swelling
- Water retention or tingling in extremities
- Transient flushing or lightheadedness
- Increased appetite from ghrelin-receptor activity
- Mild headache or fatigue
Common Dosing
As a proprietary blend, research-literature analogs are studied at roughly 100-300 mcg of each secretagogue component per administration, 1-2 times daily, often pre-sleep or fasted. For research-use only; not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active malignancy or history of cancer
- Pregnancy or breastfeeding
- Known hypersensitivity to GHRH or ghrelin-receptor analogs
Sermorelin / Ipamorelin Blend
A widely studied research blend combining the GHRH analog Sermorelin with the highly selective ghrelin-receptor agonist Ipamorelin. It is examined for clean, synergistic growth hormone release with minimal off-target effects.
CJC-1295 (No DAC) / Ipamorelin / GHRP-2 Blend
This three-peptide blend pairs CJC-1295 without DAC (a GHRH analog) with two ghrelin-mimetic secretagogues, Ipamorelin and GHRP-2, to maximize a clean, synergistic growth hormone pulse. All components are unapproved research peptides.
Tesamorelin / Ipamorelin Blend
A research blend combining the visceral-fat-reducing GHRH analog Tesamorelin with the selective ghrelin agonist Ipamorelin. It is studied for synergistic GH release with a favorable metabolic profile.
- View
Ipamorelin, the first selective growth hormone secretagogue
1998